Featured Story

  • Struggling Unilife extends negotiating period with Amgen over partial takeover

    Struggling injection device specialist Unilife said in an SEC filing that it needs an additional week to negotiate a deal with potential savior Amgen, which would involve the big biotech purchasing up to 19.9% of the company's stock in return for a much-needed cash infusion. If the grand alliance pans out, Amgen would also gain the preferred right of access to new drug delivery platforms and enter into a manufacturing arrangement with Unilife.

'Crystal balls' in drug delivery could be stronger than liposomes

Researchers at Philadelphia's Drexel University have developed a microscopic "crystal ball" that could someday be used for drug delivery.

Scilex aims to dethrone Endo in billion-dollar pain subsegment using novel transdermal patch

Malvern, PA's Scilex Pharmaceuticals is seeking to deploy its transdermal drug delivering patch to break into the post-herpetic neuralgia market, which is led by an Endo drug that had peak sales of $1.4 billion.

Spero Therapeutics raises $30M to support its drug delivery platform targeting Gram-negative bacteria

Cambridge, MA's Spero Therapeutics has raised $30 million in Series B financing to develop its so-called Potentiator Platform to improve existing antibiotics by enabling them to pass through the cell membrane of Gram-negative bacteria.

FDA says drug delivery devices need human factors validation testing

Several drug delivery devices are on a draft list of med tech that will be subject to a final guidance calling for the application of human factors and usability engineering to medical devices.

Novartis signs with France's MedinCell for controlled-release injection tech

French drug delivery specialist MedinCell is teaming up with Novartis' generic division Sandoz to develop controlled-release drugs with a focus on cancer.


From Our Sister Sites


‚ÄčIn this week's EuroBiotech Report, the results from a Phase I trial of Heptares' muscarinic M1 receptor agonist have added to its belief that its pursuit of an Alzheimer's disease target that stumped Eli Lilly can pay off. And more.


Johnson & Johnson sees big things ahead for California's NeuroVision, so it's expanding its partnership with the company. The move gives NeuroVision a boost as it looks to grab a bigger piece of the market for its Alzheimer's eye-imaging diagnostic.